DaVita Clinical Research Presents Research Results at the American Nephrology Nurses Association National Symposium

DaVita Clinical Research® (DCR®) (NYSE: DVA), a specialty contract research organization with services spanning the full spectrum of drug and device development, today announced that company representatives will present four abstracts at the American Nephrology Nurses Association (ANNA) National Symposium scheduled for April 21-24, 2013 in Las Vegas, Nevada.

With a membership of more than 10,000 registered nurses and other health care professionals, the mission of ANNA is to promote excellence in nephrology nursing and appreciation of the profession in order to make a positive difference for people with kidney disease.

Researchers from DaVita®, the dialysis division of DaVita Healthcare Partners Inc., and DCR will present results from a number of innovative clinical improvement programs originating from DaVita and its research partners.

“At DaVita, we’re committed to furthering education and improving clinical outcomes, which we feel is reflected in our studies,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical research at DaVita. “It’s ideal to present these findings at ANNA, where health care professionals collaborate on ways to improve the quality of life for kidney patients.”

At this year's ANNA meeting, researchers from DCR and DaVita will focus on several key research initiatives in end-stage renal disease, including:

• “Decreasing Peritonitis Rate in Peritoneal Dialysis Resulting in Lower Mortality and Technique Failure” Oral presentation by Tracey Milligan, DaVita regional operations director, on Monday, April 22, in Abstract Concurrent Session #161, from 5:40 p.m. – 5:55 p.m.
• “Extracellular Volume Control in Dialysis Patients to Reduce Hospitalizations.” Oral presentation by Irina Goykhman, vice president of clinical improvement at DaVita, on Monday, April 22, in Abstract Concurrent Session #162, from 5:20 p.m. – 5:35 p.m.
• “Hemoglobin Trends in Incident End-Stage Renal Disease Patients from 2008-2012” Poster presentation by Deuzimar Kulawik, director, office of the chief medical officer at DaVita
• “Implementation of Electrolytically-Produced Sodium Hypochlorite Protocol Improved Peritonitis Rates” Poster presentation by Tracey Milligan

DCR provides a collaborative bridge between DaVita’s health care community and the academic, pharmaceutical and biotech research community. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

To learn more about DCR and upcoming clinical trials, please visit www.ParticipateDaVita.com.

DaVita, DaVita Clinical Research, DCR and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita Healthcare Partners Inc. All other trademarks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Dec.31, 2012, DaVita operated or provided administrative services at 1,954 outpatient dialysis centers located in the United States serving approximately 153,000 patients. The company also operated 36 outpatient dialysis centers located in eight countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of clinical trials including retrospective and prospective pragmatic trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR’s Biorepository, Early Clinical Research unit (Phase I-IIa) and Clinical Development (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes Research, Central Laboratory, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.